What is ZG Biotech?
Established in 2017, ZG Biotech has emerged as a leader in the development and manufacturing of macromolecular medicines. The company is primarily recognized for its industry-leading large-scale animal cell culture technology, a core competency that differentiates it from traditional biopharmaceutical service providers. By integrating advanced R&D with robust manufacturing processes, ZG Biotech provides essential support to the life sciences industry, facilitating the development of complex therapeutic agents. Its market position is defined by a commitment to technical excellence and the ability to navigate the rigorous demands of global pharmaceutical supply chains.
How much funding has ZG Biotech raised?
ZG Biotech has raised a total of $100M across 1 funding round:
Series C
$100M
Series C (2022): $100M with participation from Junxin Capital, Goldman Sachs Asset Management, Qiming Venture Partners, Novo Holdings, Sofina, Cowincapital, LYFE Capital, and IDG Capital Partners
Key Investors in ZG Biotech
Qiming Venture Partners
A prominent venture capital firm focusing on innovative companies across technology, healthcare, and artificial intelligence, providing strategic guidance and industry resources.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, specializing in long-term life science investments.
Sofina
A Belgian private equity and venture capital firm that specializes in growth capital and direct investments across healthcare, digital transformation, and consumer sectors.
What's next for ZG Biotech?
Looking ahead, the strategic deployment of the $100M will likely focus on the expansion of manufacturing capacity and the enhancement of its R&D pipeline. As the company matures, the focus will shift toward achieving greater economies of scale and deepening its integration into international healthcare markets. The backing from a consortium of high-profile institutional investors suggests a clear path toward potential public market entry or further industry consolidation. ZG Biotech is expected to leverage its current momentum to secure its status as a preferred partner for global biopharmaceutical firms seeking reliable, high-quality production capabilities.
See full ZG Biotech company page
